{"generic":"Haemophilus B Conjugate and Hepatitis B Vaccine","drugs":["Comvax","Haemophilus B Conjugate and Hepatitis B Vaccine"],"mono":{"0":{"id":"924142-s-0","title":"Generic Names","mono":"Haemophilus B Conjugate and Hepatitis B Vaccine"},"1":{"id":"924142-s-1","title":"Dosing and Indications","sub":{"1":{"id":"924142-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy not established in infants younger than 6 weeks of age and older than 15 months<\/li><li><b>Haemophilus influenza B and hepatitis B vaccination:<\/b> (hepatitis B surface antigen (HBsAg)-negative mother) 0.5 mL IM x 3 doses given at 2, 4, and 12 to 15 months of age (at least a 6-week interval between doses 1 and 2 and an 8- to 11-month interval between doses 2 and 3).<\/li><\/ul>"},"3":{"id":"924142-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Haemophilus influenza B and hepatitis B vaccination<br\/>"}}},"3":{"id":"924142-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924142-s-3-9","title":"Contraindications","mono":"<ul><li>age less than 6 weeks; reduced immune response and potential for immune tolerance to future injections<\/li><li>hypersensitivity to yeast, to any component of the vaccine (manufacturer); allergic reaction, severe (eg, anaphylaxis) after a previous dose or to a vaccine component<\/li><li>symptoms suggestive of hypersensitivity after vaccination with the vaccine<\/li><\/ul>"},{"id":"924142-s-3-10","title":"Precautions","mono":"<ul><li>acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>adults; not recommended for use<\/li><li>bleeding disorders (eg, hemophilia, thrombocytopenia); take proper precautions to avoid hematoma risk following vaccination<\/li><li>hypersensitivity reaction, including anaphylaxis may occur<\/li><li>immunocompromised patients, including those with malignancies or receiving immunosuppressive drugs; diminished immune response may occur; consider deferring vaccination in patients on immunosuppressive therapy<\/li><li>IM administration only; avoid injecting into a blood vessel<\/li><li>latex sensitivity; vial stopper contains dry, natural latex rubber<\/li><li>report suspected adverse events to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or www.vaers.hhs.gov<\/li><\/ul>"},{"id":"924142-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"924142-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"924142-s-4","title":"Drug Interactions","sub":{"1":{"id":"924142-s-4-14","title":"Major","mono":"<ul>Cyclosporine (theoretical)<\/ul>"}}},"5":{"id":"924142-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (22.4% to 27.2%), Injection site pain (23.9% to 34.5%), Swelling at injection site (27.2% to 30.4%)<\/li><li><b>Neurologic:<\/b>Somnolence (21.1% to 49.5%)<\/li><li><b>Psychiatric:<\/b>Crying, Prolonged (0.2% to 2.4%), Crying, Unusual, High-Pitched (2.9% to 10.6%), Irritability (32.2% to 57%)<\/li><li><b>Other:<\/b>Fever (10.5% to 14.2%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Dermatologic:<\/b>Erythema multiforme<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Neurologic:<\/b>Febrile seizure, Seizure<\/li><\/ul>"},"6":{"id":"924142-s-6","title":"Drug Name Info","sub":{"0":{"id":"924142-s-6-17","title":"US Trade Names","mono":"Comvax<br\/>"},"2":{"id":"924142-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"924142-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"924142-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"924142-s-7","title":"Mechanism Of Action","mono":"The combination haemophilus b conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine (Comvax(R)) is a bivalent vaccine containing antigenic components of the haemophilus influenza type b capsular polysaccharide (polyribosylribitol phosphate) covalently bound to an outer membrane protein complex of Neisseria meningitidis and hepatitis B surface antigen from recombinant yeast cultures. Comvax(R) works by inducing protective antibodies to haemophilus influenza type b infection and all known subtypes of hepatitis B virus.<br\/>"},"9":{"id":"924142-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>IM use only; do not inject IV, intradermally, or subQ<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>shake well before use<\/li><li>inject into anterolateral aspect of the thigh<\/li><li>may be administered concomitantly with diphtheria, tetanus, whole-cell pertussis vaccine (DTP); diphtheria, tetanus, and acellular pertussis vaccine (DTaP); oral poliovirus vaccine (OPV); inactivated poliomyelitis vaccine (IPV); mumps, measles, and rubella vaccine (MMR); and varicella virus vaccine, live<\/li><\/ul><\/li><\/ul>"},"10":{"id":"924142-s-10","title":"Monitoring","mono":"no specific monitoring has been determined<br\/>"},"11":{"id":"924142-s-11","title":"How Supplied","mono":"<b>Comvax<\/b><br\/>Intramuscular Suspension: (Haemophilus B Conjugate Vaccine - Hepatitis B Vaccine Recombinant) 7.5 MCG\/0.5 ML-5 MCG\/0.5 ML<br\/>"},"13":{"id":"924142-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause injection site reactions, somnolence, irritability, and fever.<\/li><li>Review dosing schedule with caregiver.<\/li><li>Inform caregiver of the importance of the child receiving the entire series of vaccinations. If a dose is missed, another appointment should be scheduled as soon as possible.<\/li><\/ul>"}}}